IL249692A0 - Analogues of hepcidin and mini-hepcidin and their uses - Google Patents
Analogues of hepcidin and mini-hepcidin and their usesInfo
- Publication number
- IL249692A0 IL249692A0 IL249692A IL24969216A IL249692A0 IL 249692 A0 IL249692 A0 IL 249692A0 IL 249692 A IL249692 A IL 249692A IL 24969216 A IL24969216 A IL 24969216A IL 249692 A0 IL249692 A0 IL 249692A0
- Authority
- IL
- Israel
- Prior art keywords
- hepcidin
- mini
- analogues
- uses therof
- therof
- Prior art date
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title 1
- 102000018511 hepcidin Human genes 0.000 title 1
- 229940066919 hepcidin Drugs 0.000 title 1
- 108060003558 hepcidin Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018382P | 2014-06-27 | 2014-06-27 | |
| PCT/US2015/038370 WO2015200916A2 (en) | 2014-06-27 | 2015-06-29 | Hepcidin and mini-hepcidin analogues and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL249692A0 true IL249692A0 (en) | 2017-02-28 |
Family
ID=54938965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249692A IL249692A0 (en) | 2014-06-27 | 2016-12-21 | Analogues of hepcidin and mini-hepcidin and their uses |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170313754A1 (enExample) |
| EP (1) | EP3161164A4 (enExample) |
| JP (1) | JP2017523959A (enExample) |
| KR (1) | KR20170043509A (enExample) |
| CN (1) | CN107075574A (enExample) |
| AU (1) | AU2015279571A1 (enExample) |
| CA (1) | CA2953721A1 (enExample) |
| IL (1) | IL249692A0 (enExample) |
| SG (1) | SG11201610799WA (enExample) |
| WO (1) | WO2015200916A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448382C (en) | 2001-05-25 | 2013-02-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin as a regulator of iron homeostasis |
| KR102236829B1 (ko) * | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 유사체 및 이의 용도 |
| US11504346B2 (en) | 2013-11-03 | 2022-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redox-activated pro-chelators |
| US12383518B2 (en) | 2013-11-03 | 2025-08-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Disulfide-masked pro-chelator compositions and methods of use |
| AU2015258863B2 (en) | 2014-05-16 | 2019-10-24 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| AU2015289642B2 (en) | 2014-07-17 | 2021-02-25 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2017117411A1 (en) * | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| KR20180109917A (ko) * | 2016-01-08 | 2018-10-08 | 라 졸라 파마슈티칼 컴파니 | 헵시딘의 투여 방법 |
| EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS |
| AU2017324446A1 (en) * | 2016-09-06 | 2019-03-28 | La Jolla Pharmceutical Company | Methods of treating iron overload |
| AU2017378976A1 (en) * | 2016-12-19 | 2019-07-04 | La Jolla Pharmaceutical Company | Methods of administering hepcidin |
| WO2018128828A1 (en) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| US20200170971A1 (en) * | 2017-07-18 | 2020-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Disulfide-masked pro-chelator compositions and methods of use |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| US11286243B2 (en) | 2018-12-13 | 2022-03-29 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
| CN114585637B (zh) | 2019-05-07 | 2025-04-15 | 拜耳公司 | Masp抑制化合物及其用途 |
| MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| EP4025592B1 (en) * | 2019-09-03 | 2025-10-29 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics for use in treating of polycythemia vera |
| WO2021062171A1 (en) * | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
| JP2022549506A (ja) * | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| KR20220141808A (ko) | 2020-01-15 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도 |
| CN118063554A (zh) | 2020-01-15 | 2024-05-24 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| CA3181577A1 (en) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Thieno pyrimidines as ferroportin inhibitors |
| PE20230845A1 (es) | 2020-04-28 | 2023-05-23 | Global Blood Therapeutics Inc | Pirimidinas cicloalquiladas como inhibidores de la ferroportina |
| US20230226074A1 (en) | 2020-04-28 | 2023-07-20 | Global Blood Therapeutics, Inc. | Methods of use for pyrimidines as ferroportin inhibitors |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN111560051B (zh) * | 2020-05-26 | 2022-11-25 | 大连工业大学 | 一种具有促铁吸收活性的虾源九肽及其应用 |
| US20230324413A1 (en) * | 2020-07-02 | 2023-10-12 | Tampere University Foundation Sr | Renin-based analysis of hepcidin |
| KR20230053615A (ko) * | 2020-07-28 | 2023-04-21 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 접합된 헵시딘 모방체 |
| CN114252627A (zh) * | 2020-09-24 | 2022-03-29 | 首都医科大学附属北京世纪坛医院 | 尿液铁调素及其多肽片段在过敏性疾病中的应用 |
| KR20230110570A (ko) | 2020-11-20 | 2023-07-24 | 얀센 파마슈티카 엔.브이. | 인터류킨-23 수용체의 펩티드 억제제의 조성물 |
| WO2022212696A1 (en) * | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2022266060A1 (en) | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| TW202330013A (zh) | 2021-07-14 | 2023-08-01 | 美商健生生物科技公司 | 介白素－２３受體之脂化肽抑制劑 |
| CN115703826B (zh) * | 2021-08-03 | 2025-05-06 | 浙江大学 | 铁调素改造体及其应用 |
| EP4587034A1 (en) * | 2022-09-15 | 2025-07-23 | Migal Galilee Research Institute Ltd | Site-specific activation of regulatory t cells |
| WO2025224128A1 (en) | 2024-04-24 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065083A1 (es) * | 2007-02-02 | 2009-05-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| CN101358201A (zh) * | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
| CN101307085B (zh) * | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
| GR1006896B (el) * | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2010065815A2 (en) * | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| US20130236977A1 (en) * | 2010-05-24 | 2013-09-12 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
| BR112014013697A2 (pt) * | 2011-12-09 | 2020-11-03 | The Regents Of The University Of California | peptídeos mini-hepcidina modificados e métodos de uso dos mesmos |
| KR102236829B1 (ko) * | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 헵시딘 유사체 및 이의 용도 |
-
2015
- 2015-06-29 WO PCT/US2015/038370 patent/WO2015200916A2/en not_active Ceased
- 2015-06-29 KR KR1020177002630A patent/KR20170043509A/ko not_active Withdrawn
- 2015-06-29 US US15/321,124 patent/US20170313754A1/en not_active Abandoned
- 2015-06-29 EP EP15812513.8A patent/EP3161164A4/en not_active Withdrawn
- 2015-06-29 AU AU2015279571A patent/AU2015279571A1/en not_active Abandoned
- 2015-06-29 JP JP2016575360A patent/JP2017523959A/ja not_active Withdrawn
- 2015-06-29 CA CA2953721A patent/CA2953721A1/en not_active Abandoned
- 2015-06-29 CN CN201580043057.2A patent/CN107075574A/zh active Pending
- 2015-06-29 SG SG11201610799WA patent/SG11201610799WA/en unknown
-
2016
- 2016-12-21 IL IL249692A patent/IL249692A0/en unknown
-
2019
- 2019-06-12 US US16/439,435 patent/US20200017566A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3161164A2 (en) | 2017-05-03 |
| US20170313754A1 (en) | 2017-11-02 |
| EP3161164A4 (en) | 2018-04-25 |
| JP2017523959A (ja) | 2017-08-24 |
| CA2953721A1 (en) | 2015-12-30 |
| SG11201610799WA (en) | 2017-01-27 |
| US20200017566A1 (en) | 2020-01-16 |
| CN107075574A (zh) | 2017-08-18 |
| WO2015200916A2 (en) | 2015-12-30 |
| AU2015279571A1 (en) | 2017-02-02 |
| KR20170043509A (ko) | 2017-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201610799WA (en) | Hepcidin and mini-hepcidin analogues and uses therof | |
| IL259367B (en) | Promoters and their uses | |
| IL241043B (en) | Pesidine analogues and their uses | |
| IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
| IL247014A0 (en) | 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use | |
| EP3129382A4 (en) | Azaazene analogues and their use as semiconductor | |
| HUE044571T2 (hu) | Módosított ciklopentapeptidek és alkalmazásaik | |
| PL3368514T3 (pl) | Trójpodstawione sililofenoksyheterocykle i analogi | |
| GB201401617D0 (en) | Novel combination and use | |
| GB201617085D0 (en) | Compare and delay instructions | |
| SI3233105T1 (sl) | Nove kombinacije in uporaba | |
| GB201400521D0 (en) | Biomarker and uses thereof | |
| IL256020B (en) | Igfbp3 and uses thereof | |
| ZA201801052B (en) | Combinations and uses thereof | |
| SG11201701717UA (en) | Antiviral agents and uses thereof | |
| GB2530558B (en) | Carabiner | |
| IL254241A0 (en) | Etv2 and its uses | |
| GB201408091D0 (en) | Methods and uses | |
| GB201407532D0 (en) | Apelin analogues | |
| GB201401673D0 (en) | Esculentin-2CHa peptide and analogues thereof | |
| HK1237823A1 (en) | Hepcidin and mini-hepcidin analogues and uses therof | |
| GB2545167B (en) | Cloches and use thereof | |
| PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
| GB201416086D0 (en) | Methods and uses | |
| GB201416073D0 (en) | Methods and uses |